Pharmacokinetics of the Bovine Formulation of Enrofloxacin (Baytril 100) in Horses
|
|
- Benjamin Price
- 6 years ago
- Views:
Transcription
1 C. Boeckh, C. Buchanan, A. Boeckh, S. Wilkie, C. Davis, T. Buchanan, and D. Boothe Pharmacokinetics of the Bovine Formulation of Enrofloxacin (Baytril 100) in Horses Christine Boeckh, DVM, MS a Charles Buchanan, DVM a Albert Boeckh, DVM b Scott Wilkie, BS b Cal Davis, DVM a Terrell Buchanan, DVM a Dawn Boothe, DVM, PhD b a Brazos Valley Equine Hospital 6999 Highway 6 Navasota, TX b Department of Veterinary Physiology and Pharmacology College of Veterinary Medicine Texas A&M University College Station, TX ABSTRACT Following approval of a concentrated injectable formulation of enrofloxacin for cattle (Baytril 100 Injectable, Bayer Corp. Agricultural Division, Shawnee Mission, KS), equine practitioners have started administering this preparation both parenterally and orally to horses, despite the lack of pharmacokinetic data in this species. Six healthy horses received enrofloxacin at 7.5 mg/kg both orally and intravenously, with the sequence being randomly assigned and at least 1 week of washout allowed between administrations. Blood samples were collected from each horse at various intervals after drug administration to study the pharmacokinetic profile of this product. As concentration-dependent antimicrobials, fluorinated quinolones such as enrofloxacin are most efficacious when the inhibitory quotient is at least 8. In this study, based on inhibitory quotients between 8 and 10, the bovine injectable formulation of enrofloxacin administered to horses intravenously or orally once daily at 7.5 mg/kg may be effective against susceptible organisms whose minimum inhibitory concentration for 90% of the isolates is lower than 0.5 µg/ml. INTRODUCTION Enrofloxacin is a popular fluorinated quinolone antimicrobial recently approved in the United States for treatment of bovine respiratory disease. This formulation of enrofloxacin (Baytril 100 Injectable, Bayer Corp. Agricultural Division, Shawnee Mission, KS) is an arginine-based injectable product containing 100 mg enrofloxacin per ml. Other approved formulations include tablets (27, 68, and 136 mg) and injectable (2.27 mg/ml) for use in small animals. Although not approved for use in horses, equine practitioners have taken advantage of the potential therapeutic ben- 129
2 Veterinary Therapeutics Vol. 2, No. 2, Spring 2001 efits of enrofloxacin, using both the oral and injectable small animal formulations for treatment of bacterial infections in their patients. Previous reports support the efficacy and safety of enrofloxacin in horses. 1 3 One disadvantage of using small animal formulations of enrofloxacin, however, is the number of tablets or volume of the injectable product needed to administer an appropriate dose to an adult horse. Following approval of the concentrated injectable formulation of enrofloxacin for cattle, equine practitioners have started administering this preparation both parenterally and orally to horses, despite the lack of pharmacokinetic data in this species. The objective of this study was to establish the pharmacokinetic profile, including bioavailability, of the bovine arginine-based enrofloxacin formulation (Baytril 100 Injectable) administered either intravenously or orally in horses. MATERIALS AND METHODS Horses Six healthy adult horses (four geldings and two mares), weighing from 400 to 450 kg each and ranging in age from 3 to 8 years, were selected for the study. The study design was reviewed and approved by the Texas A&M University Veterinary Clinical Research Committee, which assures the humane and ethical use of client-owned animals in research. Animals were individually housed in stalls at a private equine referral hospital and fed commercial equine pellet food and coastal hay. Each horse received the drug both orally and intravenously, with the sequence being randomly assigned and at least 1 week of washout allowed between administrations. All horses received a thorough physical examination at the start of the trial and were clinically healthy throughout the study. Treatment Animals initially received enrofloxacin at 7.5 mg/kg on Day 0 either intravenously or orally. This dosage rate is within the range used in dogs and cats (5 20 mg/kg) as well as for treatment of bovine respiratory disease ( mg/kg). On the day of treatment, animals treated intravenously were fitted with two jugular catheters, the right one for drug administration and the left one for blood sample collection. The right catheter was removed immediately after drug administration, and the left catheter remained for the duration of sample collection. When receiving the drug orally, animals were fitted with only one catheter; a nasogastric tube was used for drug administration, ensuring that no drug loss would occur during dosing. Evaluations A blood sample (7 ml) was collected from each horse through the left jugular catheter, transferred to glass tubes, and allowed to clot at room temperature. Blood samples were collected immediately before dosing and 2, 5, 10, 15, 20, 30, 45 minutes and 2, 3, 4, 6, 8, 10, and 12 hours after intravenous administration. Samples were collected immediately before dosing and 15, 30, 45, 60, 90 minutes and 2, 3, 4, 6, 8, and 12 hours after oral dosing. Clotted blood samples were centrifuged at 1250 g for harvesting of the serum. Serum was frozen at 20 C until analysis, which occurred within 1 month of sample collection. One standard of a known concentration of enrofloxacin prepared in equine serum was frozen and analyzed with each batch of samples for assurance of sample stability during storage. Samples were analyzed by high-performance liquid chromatography using a procedure previously described and validated for simultaneous measurement of both enrofloxacin and its active metabolite ciprofloxacin. 4 Briefly, samples were defrosted and centrifuged through a 10-kD membrane at 1750 g for 2 hours. After 130
3 C. Boeckh, C. Buchanan, A. Boeckh, S. Wilkie, C. Davis, T. Buchanan, and D. Boothe centrifugation, enrofloxacin and ciprofloxacin were separated from one another and from other serum constituents by a reverse phase C- 18 column, then detected and quantified by fluorescence with excitation at 280 nm and detection at 450 nm. The lower and upper limits of quantification for this study were 0.06 and 6.79 µg/ml, respectively, for enrofloxacin and 0.02 and 6.75 µg/ml for ciprofloxacin. Precision was 91.8% for enrofloxacin and 91.3% for ciprofloxacin; accuracy was 105.8% for enrofloxacin and 110.0% for ciprofloxacin. Analysis Serum concentrations versus time were subjected to linear regression using computer modeling software for determination of maximum concentration (C max ); time to maximum concentration (T max ); area under the concentration versus time curve (AUC) to infinity by the trapezoid method; mean residence time (MRT); appearance (k a ) and disappearance (k el ) constants; appearance (t1/2a) and disappearance (t1/2) half-lives; clearance (Cl); apparent volume of distribution (Vd); rate constant for the terminal portion of the curve (Beta); y intercept for the terminal portion of the curve (B); and bioavailability (F) (Table 1). The model selected for each animal was always that which minimized residuals, based on Akaike s method for modeling criteria. 5 Appearance and disappearance rate constants were determined, respectively, from the initial and terminal components of the plasma drug concentration versus time curves. 6 Each rate constant was used to determine respective t1/2a and t1/2. 7 Inhibitory quotients (IQs; peak serum concentrations: minimum inhibitory concentration [MIC] ratio of the infecting microbe) for selected pathogens were calculated using previously published MIC data from large animal field isolates. 8 Descriptive statistics were reported for enrofloxacin and ciprofloxacin as the mean ± standard deviation. Pharmacokinetic data were evaluated for statistical significance using Student s t-test. Differences were considered to be significant at P.05. RESULTS There was no indication of drug degradation during storage. After intravenous administration of enrofloxacin, mean serum concentrations, extrapolated from the terminal phase (B), were 4.31 ± 3.43 µg enrofloxacin/ml and 0.37 ± 0.11 µg ciprofloxacin/ml (Table 1, Figure 1). After oral administration, mean C max was 2.2 ± 0.71 µg/ml for enrofloxacin and 0.38 ± 0.12 µg/ml for ciprofloxacin. Times to peak concentrations were similar for the two compounds: ± minutes for enrofloxacin and ± minutes for ciprofloxacin (Table 1, Figure 1). The t1/2 of ciprofloxacin was longer than for the parent compound after intravenous administration but not after oral dosing (Table 1). Bioavailability of enrofloxacin in this study was 65.6% ± 14.9%. Significant differences between the routes of administration were not detected for any variable measured. Inhibitory quotients for enrofloxacin, based on B for intravenous administration and on C max for oral administration, divided by the MIC for 90% of selected isolates (MIC 90 ), 8,9 ranged from 3.6 to 150 for the isolates evaluated (Table 2). DISCUSSION Results of this study suggest that oral or intravenous administration of a commercially available bovine injectable formulation of enrofloxacin is potentially useful as an antimicrobial for horses. The calculated apparent Vd of enrofloxacin was 2.49 L/kg, consistent with results (2.9 L/kg) from a previous equine study using the same dosage rate 10 as well as a canine 131
4 Veterinary Therapeutics Vol. 2, No. 2, Spring 2001 TABLE 1. Selected Pharmacokinetic Parameters for Enrofloxacin and Ciprofloxacin After Intravenous or Oral Administration of Enrofloxacin at 7.5 mg/kg Intravenous Oral Enrofloxacin Ciprofloxacin Enrofloxacin Ciprofloxacin Mean SD Mean SD Mean SD Mean SD C max (µg/ml) NA NA T max (hr) NA NA AUC ([ug/ml] hr) t1/2a (hr) NA NA t1/2 (hr) MRT (hr) K a (hr 1 ) NA NA K el (hr 1 ) B (µg/ml) Beta (hr 1 ) Vd (B) (L/kg) NA NA NA NA NA NA Vd (area) (L/kg) NA NA NA NA NA NA Cl (ml/kg/h) NA NA NA NA NA NA F (%) NA NA NA NA NA NA AUC = area under the concentration versus time curve; B = Y intercept for the terminal portion of the curve; Beta = rate constant for the terminal portion of the curve; Cl = clearance; C max = maximum concentration; F = bioavailability; k a = appearance constant; k el = disappearance constant; MRT = mean residence time; NA = not applicable; t1 /2a = appearance half-life; t1 /2 = disappearance half-life; T max = time to maximum concentration; Vd (area) = apparent volume of distribution (area); Vd (B) = apparent volume of distribution (B) Concentration (µg/ml) Enrofloxacin (intravenous treatment) Enrofloxacin (oral treatment) Ciprofloxacin (intravenous treatment) Ciprofloxacin (oral treatment) Time (hr) Figure 1. Mean (± SD) concentrations of enrofloxacin and its metabolite, ciprofloxacin, after intravenous or oral administration of enrofloxacin at 7.5 mg/kg. 132
5 C. Boeckh, C. Buchanan, A. Boeckh, S. Wilkie, C. Davis, T. Buchanan, and D. Boothe TABLE 2. MIC 90 and Inhibitory Quotients for Enrofloxacin, Ciprofloxacin, and Enrofloxacin + Ciprofloxacin against Selected Pathogenic Organisms Pasteurella Escherichia coli multocida Salmonella Mycoplasma (n = 109) (n = 63) (n = 234) (n = 18) MIC 90 (µg/ml) INHIBITORY QUOTIENTS Intravenous enrofloxacin Intravenous ciprofloxacin Intravenous enrofloxacin + ciprofloxacin Oral enrofloxacin Oral ciprofloxacin Oral enrofloxacin + ciprofloxacin MIC 90 = minimum inhibitory concentration for 90% of the isolates. study in which Vd ranged from 1.2 to 3.4 L/kg. 11 The large Vd suggests lipid solubility and good distribution into tissues, an important attribute for efficacy of an antimicrobial. Bioavailability of enrofloxacin in this study (65.6%) was lower than previously reported (78.3%) in horses 10 or other species, such as dogs and cats. 12 Nevertheless, a dosage rate of 7.5 mg/kg should provide sufficient tissue drug concentrations to ensure efficacy, based on the lipid solubility and the high Vd of enrofloxacin. Elimination half-life (t1/2) in horses in this study was more than twice as long as previously reported in dogs 11 but similar to another study in horses in which the t1/2 was 6.1 hours after intravenous injection of enrofloxacin at 5 mg/kg. 13 This longer half-life may be an advantage in horses because the drug will have longer contact with the bacterial organism. However, because fluorinated quinolones as a class are described as concentration dependent, the clinical relevancy of a longer half-life is not clear. Indeed, these drugs can be administered once daily despite a relatively short half-life. As concentration-dependent antimicrobials, fluorinated quinolones such as enrofloxacin are most efficacious when the IQ is at least The MIC 90 for enrofloxacin and pathogenic organisms in horses apparently has not been published. Although IQ data in this study are based on MIC 90 data cultured from bovine rather than equine samples, they can provide a useful guide for pathogens infecting horses. The IQ does not take into consideration the active metabolite ciprofloxacin, which acts in an additive fashion with its parent compound 15 and has similar antimicrobial activity. The combined B of enrofloxacin and ciprofloxacin was 4.7 µg/ml after intravenous administration and 2.6 µg/ml after oral administration of enrofloxacin. This additive effect should lead to a higher IQ and thus greater efficacy. CONCLUSION Based on IQs of 8 and above, the bovine injectable formulation of enrofloxacin (Baytril 100) administered to horses intravenously or orally once daily at 7.5 mg/kg may be effective against susceptible organisms whose MIC 90 is lower than 0.5 µg/ml. REFERENCES 1. Bertone AL, Tremaine WH, Macoris DG, et al: Effect of long-term administration of an injectable enrofloxacin solution on physical and musculoskeleta 133
6 Veterinary Therapeutics Vol. 2, No. 2, Spring 2001 variables in adult horses. JAVMA 217(10): , Beluche LA, Bertone AL, Anderson DE, Kohn CW, Wiesbrode SE: In vitro dose-dependent effects of enrofloxacin on equine articular cartilage. Am J Vet Res 60(5): , Langston VC, Sedrich S, Boothe DM: Disposition of single dose oral enrofloxacin in the horse. J Vet Pharmacol Ther 19(4): , Bayer Corp Agricultural Division: Method for the analysis of enrofloxacin and ciprofloxacin in canine plasma. Shawnee Mission, KS; Akaike H: An Information Criterion (AIC). Math Sci 14:5 9, Gibaldi M, Perrier D: Pharmacokinetics. 2 nd ed. New York: Marcel Dekker; 1982: Rowland M, Tozer T: Clinical Pharmacokinetics Concepts and Applications. 2 nd ed. Philadelphia, PA: Lea & Febiger; 1989: Stegemann M: Microbiology and pharmacology of enrofloxacin in cattle. Bovine Pract 31(1):76 81, Pirro F, Edinloh M, Schmeer N: Bactericidal and inhibitory activity of enrofloxacin and other fluoroquinolones in small animal pathogens. Proceedings of the Third International Symposium on Fluoroquinolones. Compend Contin Educ Pract Vet 21(Suppl): 9 25, Haines GR, Brown MP, Gronwall RR, Merritt KA. Serum concentrations and pharmacokinetics of enrofloxacin after intravenous and intragastric administration to mares. Can J Vet Res 64: , Cester CC, Schneider M, Totain PL: Comparative kinetics of two orally administered fluoroquinolones in dogs: Enrofloxacin versus marbofloxacin. Rev Med Vet 147(10): , Kung K, Riond J, Wanner M: Pharmacokinetics of enrofloxacin and its active metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs. J Vet Pharmacol Ther 16: , Guigere S, Sweeney RW, Belanger M: Pharmacokinetics of enrofloxacin in adult horses and concentration of the drug in serum, body fluids, and endometrial tissues after repeated intragastrically administered doses. Am J Vet Res 57(7): , Papich M: Comparison of fluoroquinolone antibacterials [abstract]. Proc ACVIM 17:53 55, Pirro R, Scheer M, de Jong A: Additive in vitro activity of enrofloxacin and its main metabolite ciprofloxacin. Proc 14th Ann Cong Eur Soc Vet Dermatol,
Baytril 100 (enrofloxacin) Injectable is FDA-approved for BRD control (metaphylaxis) in high-risk cattle.
Baytril 100 (enrofloxacin) Injectable is FDA-approved for BRD control (metaphylaxis) in high-risk cattle. Whether controlling or treating BRD, it s important to kill bacteria to let the calf s immune system
More informationTime Course of Enrofloxacin and Its Active Metabolite in Peripheral Leukocytes of Dogs
Time Course of Enrofloxacin and Its Active Metabolite in Peripheral Leukocytes of Dogs Albert Boeckh, DVM, DACVCP Dawn Boothe, DVM, PhD, DACVIM, DACVCP Scott Wilkie, BS Sarah Jones, DVM Department of Veterinary
More informationSZENT ISTVÁN UNIVERSITY. Doctoral School of Veterinary Science
SZENT ISTVÁN UNIVERSITY Doctoral School of Veterinary Science Comparative pharmacokinetics of the amoxicillinclavulanic acid combination in broiler chickens and turkeys, susceptibility and stability tests
More informationYou can lock the gate for seven days, but you can t stop Baytril 100 (enrofloxacin) Injectable.
You can lock the gate for seven days, but you can t stop Baytril 100 (enrofloxacin) Injectable. Baytril 100 (enrofloxacin) Injectable field trial investigates the lock the gate BRD treatment regimen. Often,
More informationTHE STABILITY OF E1VROFLOXA CIN University Undergraduate Research Fellow. A Senior Thesis. Texas ASM University.
THE STABILITY OF E1VROFLOXA CIN A Senior Thesis By Meagan A. Dodge 1997-98 University Undergraduate Research Fellow Texas ASM University Group: Biology THE STABILITY OF ENROFLOXACIN MEAGANA, DODGE Submitted
More informationEXCEDE Sterile Suspension
VIAL LABEL MAIN PANEL PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN READ SAFETY DIRECTIONS FOR ANIMAL TREATMENT ONLY EXCEDE Sterile Suspension 200 mg/ml CEFTIOFUR as Ceftiofur Crystalline Free
More informationSELECT NEWS. Florfenicol Monograph: Injectable & Oral Therapy for Swine
SELECT NEWS Florfenicol Monograph: Injectable & Oral Therapy for Swine Did you know that? Florfenicol is one of the most powerful antibiotics currently available in veterinary medicine with one of the
More informationComparative analysis of enrofloxacin pharmacokinetics in dogs and cats
860 Bulgarian Journal of Agricultural Science, 19 (No 4) 2013, 860-865 Agricultural Academy Comparative analysis of enrofloxacin pharmacokinetics in dogs and cats D. DimitroVa 1*, A. Dimitrova 2 and D.
More informationSUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS (Based on the current SPC of the reference product Baytril RSI 100 mg/ml Injektionslösung für Rinder und Schweine) 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT
More informationCAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
PFIZER INC. PFIZER ANIMAL HEALTH USA Product Label http://www.vetdepot.com 235 E. 42ND ST., NEW YORK, NY, 10017 Telephone: 269 833 4000 Customer Service: 800 733 5500 and 800 793 0596 Veterinary Medical
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare 20 mg/ml solution for injection for cattle and pigs (UK, IE, FR) Odimar 20 mg/ml solution for injection for cattle
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrocare 50 mg/ml Solution for Injection for Cattle, Pigs, Dogs and Cats (UK, IE, FR) Floxadil 50 mg/ml Solution for Injection
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/389/98-FINAL July 1998 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS ENROFLOXACIN (extension to
More information1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Summary of Prodcuct Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrox Max 100 mg/ml Solution for Injection for Cattle and Pigs Enroxal Max 100 mg/ml Solution for Injection for Cattle and
More informationSUMMARY OF PRODUCT CHARACTERISTICS
[Version 8, 10/2012] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS (Based on the current SPC of the reference product Baytril RSI 100 mg/ml Injektionslösung für Rinder und Schweine) 1 1. NAME OF THE VETERINARY
More informationTissue Concentrations of Enrofloxacin and Ciprofloxacin in Anesthetized Dogs Following Single Intravenous Administration*
Tissue Concentrations of Enrofloxacin and Ciprofloxacin in Anesthetized Dogs Following Single Intravenous Administration* Dawn M. Boothe, DVM, PhD a Albert Boeckh, DVM a Harry W. Boothe, DVM, MS b Scott
More informationPHARMACOKINETICS OF LINCOMYCIN FOLLOWING SINGLE INTRAMUSCULAR ADMINISTRATION IN GOATS MEEMANSHA SHARMA, BHASKAR VEMU & VINOD KUMAR DUMKA
International Journal of Agricultural Science and Research (IJASR) ISSN(P): 2250-0057; ISSN(E): 2321-0087 Vol. 7, Issue 2, Apr 2017, 555-560 TJPRC Pvt. Ltd. PHARMACOKINETICS OF LINCOMYCIN FOLLOWING SINGLE
More informationANNEX III LABELLING AND PACKAGE LEAFLET
ANNEX III LABELLING AND PACKAGE LEAFLET 1 A. LABELLING 2 PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE Card box and package leaflet for brown glass bottle (Type 1) 1. NAME OF THE
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amfipen LA 100 mg/ml suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each ml contains:
More informationIJCBS, 10(2016): International Journal of Chemical and Biochemical Sciences (ISSN )
IJCBS, 10(2016):10-15 International Journal of Chemical and Biochemical Sciences (ISSN 2226-9614) Journal Home page: www.iscientific.org/journal.html International Scientific Organization Quantification
More informationComparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys. Géza Sárközy
Comparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys Géza Sárközy Department of Pharmacology and Toxicology Faculty of Veterinary Science Szent István University
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC FOR ANTIMICROBIAL PRODUCTS
European Medicines Agency Veterinary Medicines and Inspections London, 12 November 2007 EMEA/CVMP/SAGAM/383441/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC
More informationKinetic Studies of Enrofloxacin after Intravenous Administration in Yak
Kinetic Studies of Enrofloxacin after Intravenous Administration in Yak Sanjib Khargharia*, Chandana Choudhury Barua**, H.N. Khanikar**, P. Mohan** * Clintox Bioservices, S.P. Biotech Park, Shameerpet,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Kelacyl 100 mg/ml, solution for injection for cattle and pigs (BG, CY, CZ, DE, EL, FR, HU, IE, IT, LT, PL, PT, RO, SK, UK)
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ENROXIL 100 mg/ml solution for injection for cattle and pigs (AT, IE, NL, UK) ENROXAL 100 mg/ml solution for injection for
More informationMARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS
MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL 10%, solution for injection for cattle and swine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Marbofloxacin...100.0
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE
European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/211249/2005-FINAL July 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE DIHYDROSTREPTOMYCIN (Extrapolation to all ruminants)
More informationSELECT NEWS. Florfenicol Monograph: Injectable Therapy for Cattle
SELECT NEWS Florfenicol Monograph: Injectable Therapy for Cattle Did you know that? Florfenicol is one of the most powerful antibiotics currently available in veterinary medicine with one of the lowest
More informationPierre-Louis Toutain, Ecole Nationale Vétérinaire National veterinary School of Toulouse, France Wuhan 12/10/2015
Antimicrobial susceptibility testing for amoxicillin in pigs: the setting of the PK/PD cutoff value using population kinetic and Monte Carlo Simulation Pierre-Louis Toutain, Ecole Nationale Vétérinaire
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationResearch Article Disposition Kinetic of Moxifloxacin following Intravenous, Intramuscular, and Subcutaneous Administration in Goats
International Scholarly Research Network ISRN Veterinary Science Volume 2011, Article ID 584342, 5 pages doi:10.5402/2011/584342 Research Article Disposition Kinetic of Moxifloxacin following Intravenous,
More informationSUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NUFLOR 300 mg/ml solution for injection for cattle and sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationFederal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.
BAYER HEALTHCARE LLC Animal Health Division USA Product Label http://www.vetdepot.com P.O. BOX 390, SHAWNEE MISSION, KS, 66201 0390 Customer Service Tel.: 800 633 3796 Customer Service Fax: 800 344 4219
More informationsingle intravenous and oral doses and after 14 repeated oral
Br. J. clin. Pharmac. (1986), 22, 21-25 The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily J. K. FAULKNER
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/MRL/728/00-FINAL April 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS STREPTOMYCIN AND
More informationPharmacokinetics and penetration of danofloxacin from the blood into the milk of cows
J. vet. Pharmacol. Therap. 21, 209±213, 1998. PHARMACOKINETICS Pharmacokinetics and penetration of danofloxacin from the blood into the milk of cows M. SHEM-TOV* O. RAV-HON{ G. ZIV{} E. LAVI A. GLICKMAN}
More informationConcentration of Enrofloxacin Residue from Tilapia (Oreochromis niloticus) Muscular That Infected by Aeromonas salmonicida
Journal of Agricultural Science and Technology A 4 (2014) 750-754 Earlier title: Journal of Agricultural Science and Technology, ISSN 1939-1250 doi: 10.17265/2161-6256/2014.09.005 D DAVID PUBLISHING Concentration
More informationEuropean Public MRL assessment report (EPMAR)
18 March 2016 EMA/CVMP/619817/2015 Committee for Medicinal Products for Veterinary Use European Public MRL assessment report (EPMAR) Gentamicin (all mammalian food producing species and fin fish) On 3
More informationDISPOSITION STUDY OF MELOXICAM ALONE AND ALONG WITH ENROFLOXACIN IN MALE BUFFALO CALVES AFTER INTRAVENOUS ROUTE
Wayamba Journal of Animal Science ISSN: 2012-578X; P322 - P326, 2012 First Submitted May 04, 2012; Number 1337248676 DISPOSITION STUDY OF MELOXICAM ALONE AND ALONG WITH ENROFLOXACIN IN MALE BUFFALO CALVES
More informationcrippling production of the bacterial cell wall that protects the cell from the external environment PS
Antibiotic Selection and Use in Cattle Dee Griffin DVM MS, Texas A&M Veterinary Medical Center, Canyon, TX 79016 Antibiotic use in food animals is increasingly scrutinized Much of the world s antibiotic
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology Unit EMEA/MRL/693/99-FINAL October 1999 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS MARBOFLOXACIN
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare flavour 80mg tablets for dogs (UK and IE) Marbocare F 80mg tablets for dogs (FR) Odimar 80mg tablets for dogs (BE,
More informationCopyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and
Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere
More informationMARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS
MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL FD 1 %, powder and solvent for solution for injection, for cats and dogs. 2. QUALITATIVE AND QUANTITATIVE
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Selectan 300 mg/ml solution for injection for cattle and swine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationComparative Evaluation of the Speed of Flea Kill of Imidacloprid and Selamectin on Dogs*
R. Everett, J. Cunningham, R. Arther, D. L. Bledsoe, and N. Mencke Comparative Evaluation of the Speed of Flea Kill of Imidacloprid and Selamectin on Dogs* Ronald Everett, PhD a Jerry Cunningham, MS a
More informationReduce the risk of recurrence Clear bacterial infections fast and thoroughly
Reduce the risk of recurrence Clear bacterial infections fast and thoroughly Clearly advanced 140916_Print-Detailer_Englisch_V2_BAH-05-01-14-003_RZ.indd 1 23.09.14 16:59 In bacterial infections, bacteriological
More informationRefusal EPAR for Naxcel
08 November 2012 EMA/CVMP/746112/2012 Veterinary Medicine and Product Data Management Type II variation (EMEA/V/C/000079/II/0013) Scope of variation: Addition of a new indication for the treatment of bovine
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Quiflor 20 mg/ml solution for injection for cattle, pigs and dogs [AT, BE, DK, DE, EL, ES IT, NL, PT, UK] Quiflox 20 mg/ml
More informationZOETIS INC. 333 PORTAGE STREET, KALAMAZOO, MI, Telephone: Customer Service: Website: EXCEDE FOR SWINE
ZOETIS INC. 333 PORTAGE STREET, KALAMAZOO, MI, 49007 Telephone: 269-359-4414 Customer Service: 888-963-8471 Website: www.zoetis.com Every effort has been made to ensure the accuracy of the information
More informationRecommended for Implementation at Step 7 of the VICH Process on 15 December 2004 by the VICH Steering Committee
VICH GL27 (ANTIMICROBIAL RESISTANCE: PRE-APPROVAL) December 2003 For implementation at Step 7 - Final GUIDANCE ON PRE-APPROVAL INFORMATION FOR REGISTRATION OF NEW VETERINARY MEDICINAL PRODUCTS FOR FOOD
More informationOral pharmacokinetics of fenbendazole in llamas, South American Camelids
Small Ruminant Research 37 (2000) 209±214 Oral pharmacokinetics of fenbendazole in llamas, South American Camelids Earnest Beier III a, Terry W. Lehenbauer b, Subbiah Sangiah a,* a Department of Anatomy,
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Amphen 200 mg/g Granules for use in drinking water for pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each g contains: Active
More informationDisposition kinetics of kanamycin in mules
VETERINARSKI ARHIV 73 (4), 221-226, 2003 Disposition kinetics of kanamycin in mules Faqir Muhammad, Faqir Hussain, Muhammad Nawaz, and Ijaz Javed* Department of Physiology and Pharmacology, Faculty of
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Revised: May 2014 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrox Flavour 150 mg Tablets for dogs (United Kingdom, Austria, Belgium, Germany, Denmark, Greece, Ireland,
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationPharmaceutical Form Ciprofloxacin 2 mg/ml Solution for infusion. Applicant Name Strength. Ciprofloxacin Nycomed. Ciprofloxacin Nycomed
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTE OF ADMINISTRATION, APPLICANT/ MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES Marketing Member State Authorisation
More informationBAYTRIL 25 FLAVOUR ANTIBACTERIAL ORAL SUSPENSION
Pack insert Issue Date: 8-4-2010 Page: 1 of 12 PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY BAYTRIL 25 FLAVOUR ANTIBACTERIAL ORAL SUSPENSION DESCRIPTION: Enrofloxacin
More informationJ. vet. Pharmacol. Therap. doi: /jvp SHORT COMMUNICATION H. K. KNYCH*, S. D. STANLEY*, R. M. ARTHUR & D. S. MCKEMIE*
J. vet. Pharmacol. Therap. doi: 10.1111/jvp.12328. SHORT COMMUNICATION Disposition of the anti-ulcer medications ranitidine, cimetidine, and omeprazole following administration of multiple doses to exercised
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT WONDERCEF powder and solvent for solution for injection for horses not intended for the production of foods for human consumption.
More informationResearch update - medicines for koalas
Sydney School of Veterinary Science istock photo Research update - medicines for koalas Merran Govendir Associate Professor in Veterinary Pharmacology merran.govendir@sydney.edu.au 1 Introduction Who we
More informationIntramuscular Pharmacokinetics and Milk Levels of Ceftriaxone in Endometritic Cows
Intramuscular Pharmacokinetics and Milk Levels of Ceftriaxone in Endometritic Cows Kumar, S., 1 * Srivastava, A. K., 2 Dumka, V. K. 3 and Kumar, N. 4 Faculty of Veterinary Sciences and Animal Husbandry,
More informationFollow this and additional works at: Part of the Pharmacology Commons, and the Veterinary Medicine Commons
Graduate Theses and Dissertations Graduate College 2014 Infection with Porcine Reproductive and Respiratory Syndrome Virus and Streptococcus suis changes the pharmacokinetics of ceftiofur hydrochloride
More informationPHARMACOKINETICS OF FLUNIXIN IN BUFFALO CALVES AFTER SINGLE INTRAMUSCULAR ADMINISTRATION. M.M. Gatne*, M.H. Yadav and T.R. Mahale
Original Article Buffalo Bulletin (December 2012) Vol.31 No.4 PHARMACOKINETICS OF FLUNIXIN IN BUFFALO CALVES AFTER SINGLE INTRAMUSCULAR ADMINISTRATION M.M. Gatne*, M.H. Yadav and T.R. Mahale ABSTRACT The
More informationComparative efficacy of DRAXXIN or Nuflor for the treatment of undifferentiated bovine respiratory disease in feeder cattle
Treatment Study DRAXXIN vs. Nuflor July 2005 Comparative efficacy of DRAXXIN or Nuflor for the treatment of undifferentiated bovine respiratory disease in feeder cattle Pfizer Animal Health, New York,
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12 1. NAME OF THE VETERINARY MEDICINAL PRODUCT HALOCUR 0.5 mg/ml oral solution for calves 2. Qualitative and quantitative composition Active substance Halofuginone
More informationCHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Antibiotics One of the most commonly used group of drugs In USA 23
More informationAuthor - Dr. Josie Traub-Dargatz
Author - Dr. Josie Traub-Dargatz Dr. Josie Traub-Dargatz is a professor of equine medicine at Colorado State University (CSU) College of Veterinary Medicine and Biomedical Sciences. She began her veterinary
More informationGENTAMICIN DISPOSITION IN CEREBROSPINAL FLUID (CSF) AND AQUEOUS HUMOUR IN HEALTHY DOGS
Trakia Journal of Sciences, Vol. 6, Suppl. 1, pp 14-18, 2008 Copyright 2007 Trakia University Available online at: http://www.uni-sz.bg ISSN 1312-1723 GENTAMICIN DISPOSITION IN CEREBROSPINAL FLUID (CSF)
More informationchoice The Rilexine Palatable Tablets First generation cephalosporin for skin infections Now registered for ONCE daily administration*
Virbac Dermatology Palatable Tablets The choice First generation cephalosporin for skin infections Now registered for ONCE daily administration* are only available under Veterinary Authorisation. www.virbac.co.nz
More informationDiscover the. Discover the. innovative science. Veraflox (pradofloxacin) Veraflox. Efficacy. Safety. Ease-of-use.
Discover the Discover the innovative science. science of Veraflox Oral Veraflox. Suspension for Cats Efficacy. Safety. Ease-of-use. An unprecedented combination of efficacy, safety and ease-of-use. Designed
More informationP Senthil Kumar, A Arivuchelvan, A Jagadeeswaran, N Punniamurthy, P Selvaraj, PN Richard Jagatheesan and P Mekala
2018; 7(4): 1003-1007 ISSN (E): 2277-7695 ISSN (P): 2349-8242 NAAS Rating: 5.03 TPI 2018; 7(4): 1003-1007 2018 TPI www.thepharmajournal.com Received: 21-02-2018 Accepted: 25-03-2018 P Senthil Kumar Department
More informationSerum chloramphenicol levels and the intramuscular bioavailability of several parenteral formulations of chloramphenicol in ruminants
Veterinary Quarterly ISSN: 0165-2176 (Print) 1875-5941 (Online) Journal homepage: http://www.tandfonline.com/loi/tveq20 Serum chloramphenicol levels and the intramuscular bioavailability of several parenteral
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cephacare flavour 50 mg tablets for cats and dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active
More informationAntimicrobial Stewardship and Use Monitoring Michael D. Apley, DVM, PhD, DACVCP Kansas State University, Manhattan, KS
Antimicrobial Stewardship and Use Monitoring Michael D. Apley, DVM, PhD, DACVCP Kansas State University, Manhattan, KS Defining antimicrobial stewardship is pivotal to our ability as veterinarians to continue
More informationPharmacological Evaluation of Amikacin in Neonates
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1975, p. 86-90 Copyright 0 1975 American Society for Microbiology Vol. 8, No. 1 Printed in U.SA. Pharmacological Evaluation of Amikacin in Neonates JORGE B.
More informationDetection of residues of quinolones in milk
Food Safety and Monitoring of Safety Aspects 77 Detection of residues of quinolones in milk Gertraud Suhren and P. Hammer Federal Dairy Research Centre, Institute for Hygiene, Hermann-Weigmann-Str. 1,
More informationFLOXYME 50 mg/ml SOLUTION FOR USE IN DRINKING WATER
FLOXYME 50 mg/ml SOLUTION FOR USE IN DRINKING WATER 1. NAME OF THE VETERINARY MEDICINAL PRODUCT FLOXYME 50 mg/ml SOLUTION FOR USE IN DRINKING WATER 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metrobactin 500 mg tablets for dogs and cats (AT, BE, BG, CY, CZ, DE, EL, ES, FR, HR, HU, IE, IT, LU, NL, PL, PT, RO, SI,
More informationDevelopment of Resistant Bacteria Isolated from Dogs with Otitis Externa or Urinary Tract Infections after Exposure to Enrofloxacin In Vitro
A. M. Brothers, P. S. Gibbs, and R. E. Wooley Development of Resistant Bacteria Isolated from Dogs with Otitis Externa or Urinary Tract Infections after Exposure to Enrofloxacin In Vitro Amy M. Brothers,
More informationIrish Greyhound Board. Scientific Advisory Committee on Doping and Medication Control. Opinion on Carprofen
Irish Greyhound Board Scientific Advisory Committee on Doping and Medication Control Opinion on Carprofen The Committee has been examining the advice it would give the Board on the threshold for carprofen
More informationSepsis is the leading cause of morbidity and mortality in
J Vet Intern Med 200;18:728 733 Pharmacokinetics of Once-Daily Amikacin in Healthy Foals and Therapeutic Drug Monitoring in Hospitalized Equine Neonates Erica Paige Bucki, Steeve Giguère, Margo Macpherson,
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Boflox flavour 20 mg tablets for dogs and cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance:
More information4.5. Special precautions for use Special precautions to be taken by person administering the veterinary medicinal product to animals
1.B1. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AMOXYCOL Soluble Powder 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: Amoxicillin trihydrate 640.0
More informationPharmacokinetics of amoxycillin and clavulanic acid in
Br. J. clin. Pharmac. (1988), 26, 385-390 Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of Augmentin B. E. DAVIES', R. BOON2, R. HORTON2,
More informationUCD VET VIEWS CALIFORNIA CATTLEMEN S MAGAZINE JANUARY 2006 ANTIBIOTIC CHOICES FOR BEEF CATTLE
UCD VET VIEWS CALIFORNIA CATTLEMEN S MAGAZINE JANUARY 2006 ANTIBIOTIC CHOICES FOR BEEF CATTLE During the last 30 plus years of practicing veterinary medicine I cannot remember a time when the beef cattle
More informationProceedings of the 13th International Congress of the World Equine Veterinary Association WEVA
www.ivis.org Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA October 3-5, 2013 Budapest, Hungary Reprinted in IVIS with the Permission of the WEVA Organizers
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Tilmovet 250 mg/ml Concentrate for Oral Solution (BE, BG, CZ, EL, HU, IE, NL, PL, RO, UK) for pigs, chickens, turkeys and
More informationLEVOFLOXACIN RESIDUES IN CHICKEN MEAT AND GIBLETS
Bulgarian Journal of Veterinary Medicine (2013), 16, Suppl. 1, 216 219 LEVOFLOXACIN RESIDUES IN CHICKEN MEAT AND GIBLETS R. KYUCHUKOVA 1, V. URUMOVA 2, M. LYUTSKANOV 2, V. PETROV 2 & A. PAVLOV 1 1 Department
More informationSummary of Product Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Enrotab 50 mg tablets for dogs
Summary of Product Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrotab 50 mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance Enrofloxacin
More informationEfficacy of DRAXXIN or Baytril for treatment of naturally occurring bovine respiratory disease in calves at 3 feedlots
August 7 Efficacy of or for treatment of naturally occurring bovine respiratory disease in calves at 3 feedlots Key Points Clinical success was significantly higher (P=.9, P=.31, P=.31) for calves treated
More informationInternational Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.
I J A P B International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access. ISSN: 2454-8375 COMPARISON OF ANTIMICROBIAL ACTIVITY AND MIC OF BRANDED
More informationTherios 300 mg and 750 mg Palatable Tablets for Dogs
Ceva Animal Health Ltd Telephone: 01494 781510 Website: www.ceva.com Email: cevauk@ceva.com Therios 300 mg and 750 mg Palatable Tablets for Dogs Species: Therapeutic indication: Active ingredient: Product:
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Cemay 50 mg/ml suspension for injection for pigs and cattle 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains: Active
More informationDETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*
44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine
More information6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS
6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS 6.1 INTRODUCTION Microorganisms that cause infectious disease are called pathogenic microbes. Although
More informationDefining Resistance and Susceptibility: What S, I, and R Mean to You
Defining Resistance and Susceptibility: What S, I, and R Mean to You Michael D. Apley, DVM, PhD, DACVCP Department of Clinical Sciences College of Veterinary Medicine Kansas State University Susceptible
More information